Anavex Life Sciences (AVXL)
Market Price (5/18/2026): $2.92 | Market Cap: $260.0 MilSector: Health Care | Industry: Biotechnology
Anavex Life Sciences (AVXL)
Market Price (5/18/2026): $2.92Market Cap: $260.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -51% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -65%, 3Y Excs Rtn is -148% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -45 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 22.76, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% Key risksAVXL key risks include [1] a negative European regulatory opinion for its lead drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -51% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -65%, 3Y Excs Rtn is -148% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -45 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 22.76, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% |
| Key risksAVXL key risks include [1] a negative European regulatory opinion for its lead drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Negative Regulatory Decision for Blarcamesine in Europe.
Anavex Life Sciences faced a significant setback with its lead drug candidate, blarcamesine, in the European market. Following a negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2025 regarding its marketing authorization application for early Alzheimer's disease, the company withdrew its application on March 25, 2026. This decision was made after feedback indicated that approval would not be supported at that time, impacting the drug's path to market in a key region.
2. Abrupt CEO Termination and Related Governance Concerns.
On April 30, 2026, Anavex's Board of Directors terminated Christopher Missling, PhD, from his position as Chief Executive Officer for "conduct that the Special Committee believed was inconsistent with Company policy," and requested his resignation from the Board. This leadership upheaval, which included the subsequent appointment of Terrie Kellmeyer, PhD, as Interim CEO on May 4, 2026, introduced substantial corporate governance concerns and leadership instability for the company.
Show more
Stock Movement Drivers
Fundamental Drivers
The -38.1% change in AVXL stock from 1/31/2026 to 5/17/2026 was primarily driven by a -3.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5172026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.70 | 2.91 | -38.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 86 | 89 | -3.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/17/2026| Return | Correlation | |
|---|---|---|
| AVXL | -38.1% | |
| Market (SPY) | 7.1% | 29.7% |
| Sector (XLV) | -5.8% | 10.9% |
Fundamental Drivers
The -63.5% change in AVXL stock from 10/31/2025 to 5/17/2026 was primarily driven by a -4.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5172026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.97 | 2.91 | -63.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 85 | 89 | -4.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/17/2026| Return | Correlation | |
|---|---|---|
| AVXL | -63.5% | |
| Market (SPY) | 9.0% | 24.6% |
| Sector (XLV) | 1.4% | 15.1% |
Fundamental Drivers
The -69.4% change in AVXL stock from 4/30/2025 to 5/17/2026 was primarily driven by a -4.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5172026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.50 | 2.91 | -69.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 85 | 89 | -4.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/17/2026| Return | Correlation | |
|---|---|---|
| AVXL | -69.4% | |
| Market (SPY) | 34.8% | 21.4% |
| Sector (XLV) | 5.1% | 20.5% |
Fundamental Drivers
The -64.3% change in AVXL stock from 4/30/2023 to 5/17/2026 was primarily driven by a -12.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5172026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.14 | 2.91 | -64.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 78 | 89 | -12.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/17/2026| Return | Correlation | |
|---|---|---|
| AVXL | -64.3% | |
| Market (SPY) | 84.7% | 26.7% |
| Sector (XLV) | 14.2% | 22.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AVXL Return | 221% | -47% | 1% | 15% | -67% | -13% | -43% |
| Peers Return | 5% | -30% | 27% | -28% | 47% | 4% | 3% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| AVXL Win Rate | 67% | 58% | 42% | 50% | 33% | 40% | |
| Peers Win Rate | 42% | 40% | 53% | 35% | 52% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| AVXL Max Drawdown | -42% | -59% | -57% | -64% | -77% | -48% | |
| Peers Max Drawdown | -67% | -55% | -54% | -65% | -49% | -30% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACAD, BIIB, ANVS, TSHA, NGNE. See AVXL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/15/2026 (YTD)
How Low Can It Go
| Event | AVXL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -15.5% | -18.8% |
| % Gain to Breakeven | 18.3% | 23.1% |
| Time to Breakeven | 21 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -37.2% | -9.5% |
| % Gain to Breakeven | 59.1% | 10.5% |
| Time to Breakeven | 42 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -27.0% | -6.7% |
| % Gain to Breakeven | 37.1% | 7.1% |
| Time to Breakeven | 621 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -55.4% | -33.7% |
| % Gain to Breakeven | 124.4% | 50.9% |
| Time to Breakeven | 219 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -53.2% | -19.2% |
| % Gain to Breakeven | 113.6% | 23.8% |
| Time to Breakeven | 68 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -32.9% | -3.7% |
| % Gain to Breakeven | 49.1% | 3.9% |
| Time to Breakeven | 25 days | 6 days |
In The Past
Anavex Life Sciences's stock fell -15.5% during the 2025 US Tariff Shock. Such a loss loss requires a 18.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AVXL | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -37.2% | -9.5% |
| % Gain to Breakeven | 59.1% | 10.5% |
| Time to Breakeven | 42 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -27.0% | -6.7% |
| % Gain to Breakeven | 37.1% | 7.1% |
| Time to Breakeven | 621 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -55.4% | -33.7% |
| % Gain to Breakeven | 124.4% | 50.9% |
| Time to Breakeven | 219 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -53.2% | -19.2% |
| % Gain to Breakeven | 113.6% | 23.8% |
| Time to Breakeven | 68 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -32.9% | -3.7% |
| % Gain to Breakeven | 49.1% | 3.9% |
| Time to Breakeven | 25 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -65.7% | -12.2% |
| % Gain to Breakeven | 191.7% | 13.9% |
| Time to Breakeven | 1905 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -65.7% | -6.8% |
| % Gain to Breakeven | 191.7% | 7.3% |
| Time to Breakeven | 1905 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -63.5% | -0.2% |
| % Gain to Breakeven | 174.0% | 0.2% |
| Time to Breakeven | 677 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -46.5% | -17.9% |
| % Gain to Breakeven | 86.9% | 21.8% |
| Time to Breakeven | 1493 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -63.6% | -53.4% |
| % Gain to Breakeven | 174.5% | 114.4% |
| Time to Breakeven | 2408 days | 1085 days |
In The Past
Anavex Life Sciences's stock fell -15.5% during the 2025 US Tariff Shock. Such a loss loss requires a 18.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Anavex Life Sciences (AVXL)
AI Analysis | Feedback
Here are 1-3 brief analogies for Anavex Life Sciences (AVXL):
- Like a clinical-stage Biogen or Eli Lilly, but entirely dedicated to developing new drugs for neurological diseases such as Alzheimer's and Parkinson's.
- Imagine a Moderna before its big breakthrough, but focused on finding treatments for challenging brain disorders instead of vaccines.
AI Analysis | Feedback
- ANAVEX 2-73: A lead drug candidate in late-stage clinical trials for various CNS diseases including Alzheimer's, Rett syndrome, and Parkinson's.
- ANAVEX 3-71: A drug candidate in early-stage clinical trials for frontotemporal dementia and other neurodegenerative diseases like Alzheimer's and Parkinson's.
- ANAVEX 1-41: A preclinical drug candidate designed to treat depression, stroke, Parkinson's, and Alzheimer's diseases.
- ANAVEX 1066: A preclinical drug candidate being developed for the potential treatment of neuropathic and visceral pain.
- ANAVEX 1037: A preclinical drug candidate aimed at treating prostate and pancreatic cancer.
AI Analysis | Feedback
Anavex Life Sciences Corp. (AVXL) is a clinical-stage biopharmaceutical company primarily engaged in the research and development of drug candidates for central nervous system (CNS) diseases.
As detailed in the background, its drug candidates, such as ANAVEX 2-73 and ANAVEX 3-71, are currently in various stages of clinical trials (Phase I, Phase II, Phase III) or preclinical development. At this clinical stage, the company does not have approved drug products on the market available for commercial sale.
Therefore, Anavex Life Sciences does not currently have major customers, as it is not yet selling products to other companies (such as distributors or pharmacies) or directly to individuals.
AI Analysis | Feedback
nullAI Analysis | Feedback
Christopher U. Missling, PhD, MS, MBA - President and CEO
Dr. Missling has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry, and investment banking. Prior to joining Anavex Life Sciences in July 2013, he served as the Chief Financial Officer of Curis and ImmunoGen. He also worked as head of financial planning on all aspects of financial strategy and M&A at Aventis (now Sanofi), and as an investment banker in healthcare at Deutsche Bank and Brimberg & Co. He holds an MS and PhD from the University of Munich and an MBA from Kellogg/WHU.
Sandra Boenisch - Principal Financial Officer
Sandra Boenisch serves as the Principal Financial Officer for Anavex Life Sciences Corp.
Juan Carlos Lopez-Talavera, MD, PhD - Senior Vice President, Head of Research and Development
Dr. Lopez-Talavera joined Anavex in May 2024, bringing over two decades of leadership experience in managing registrational clinical trials and patient engagement for approved therapeutics. He has contributed to the development and approvals of several treatments in the USA, Europe, and Asia, and previously held key leadership positions at Fractyl Health, Intercept Pharmaceuticals, AbbVie, Bristol Myers Squibb, and Roche. Before entering the biopharmaceutical industry, he was an Assistant Professor at the University of Pittsburgh Medical Center and a postdoctoral fellow at Yale University.
Terrie Kellmeyer, PhD - Senior Vice President of Clinical Development
Dr. Kellmeyer joined Anavex in May 2024 and has over 28 years of experience in the pharmaceutical industry. She has held executive leadership positions in Clinical Development, Regulatory Affairs, Clinical Operations, and Medical Affairs across various therapeutic areas. Dr. Kellmeyer earned her BS in Biotechnology from Rochester Institute of Technology, a PhD in Molecular Biology from SUNY Syracuse, and completed a Post-Doctoral Fellowship at the University of Rochester.
Wolfgang Liedtke, MD, PhD - Senior Vice President, Global Head of Neurology
Dr. Liedtke is a board-certified neurologist who brings more than 25 years of experience to his role as Senior Vice President, Global Head of Neurology at Anavex.
AI Analysis | Feedback
The key risks to Anavex Life Sciences (AVXL) are primarily associated with its status as a clinical-stage biopharmaceutical company with no commercialized products.
- Clinical Trial Outcomes and Regulatory Approval: The most significant risk is the success or failure of its drug candidates in clinical trials and the subsequent regulatory approval processes. Anavex's lead drug candidate, blarcamesine (ANAVEX 2-73), recently received an unfavorable preliminary opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for early Alzheimer's disease, citing concerns over efficacy, safety, and trial design. This constitutes a major setback for the company. Blarcamesine's trial data has been noted for inconsistencies, efficacy concerns, and a high rate of patient dropouts due to side effects. Regulatory decisions are inherently binary, and a negative outcome can be devastating for the company. Furthermore, progress in other programs, such as for Rett syndrome, has also faced mixed or negative results, failing to meet primary endpoints. The company plans to request a re-examination from the EMA and is in discussions with the U.S. FDA regarding its Alzheimer's trial results, indicating ongoing regulatory uncertainty.
- Financing and Dilution Risk: As a clinical-stage company with no commercial products, Anavex Life Sciences generates no revenue from drug sales. It relies on external funding, including grants, partnerships, and equity offerings, to finance its research and development. The company faces a high cash burn rate, and its existing "at-the-market" (ATM) offering facility (e.g., $150 million or $114.7 million remaining) can lead to significant dilution for current shareholders, particularly if regulatory or clinical setbacks occur. While the company reported a cash runway of more than three years as of mid-2025, persistent net losses and the need to fund extensive clinical programs make ongoing financing and potential dilution a critical concern.
- Reputational and Litigation Risk: Anavex has faced scrutiny regarding its past conduct and trial methodologies. A 2015 class action lawsuit accused the company and its executives of stock promotion and manipulation. More recent reports have raised concerns about manipulated trial endpoints, statistical analysis, and management practices. These issues can undermine investor confidence, impact the company's ability to form partnerships, and divert management's focus. An investigation alert issued in January 2026 highlights allegations of potentially misleading business information provided to the public. Stock price volatility, which is common in the biotech sector due to binary clinical and regulatory outcomes, also increases the risk of litigation.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Anavex Life Sciences' main products or services are:
- ANAVEX 2-73 (targeting Alzheimer's disease): The Alzheimer's disease market in the 7 Major Markets (US, EU4, UK, and Japan) was approximately USD 3,610 million in 2023 and is projected to reach USD 34,335 million by 2034. The United States accounted for approximately 54% of this market in 2023. Globally, the Alzheimer's disease market is expected to grow from USD 2.4 billion in 2023 to USD 17 billion by 2033 across eight major markets (China, France, Germany, Japan, Italy, Spain, the UK, and the US).
- ANAVEX 2-73 (targeting Rett syndrome): The global Rett syndrome market size was valued at USD 380.91 million in 2024 and is expected to reach USD 1090.73 million by 2033. Another estimate places the global market at USD 268 million in 2025, projected to reach USD 634.45 million by 2035. In North America, the market size was valued at USD 2.00 billion in 2024 and is expected to reach USD 4.04 billion by 2032. The United States held the largest revenue share in the North American market, at 68.9% in 2024.
- ANAVEX 2-73 (targeting Parkinson's disease): The global Parkinson's disease therapeutics market was valued at USD 6.2 billion in 2024 and is set to reach USD 13.3 billion by 2034. In the U.S., the Parkinson's disease treatment market was approximately USD 1,883 million in 2023, and generated USD 1,943.7 million in 2024, with projections to reach USD 2,604.0 million by 2030.
- ANAVEX 3-71 (targeting frontotemporal dementia): The global Frontotemporal Dementia market is estimated to be valued at USD 12.93 billion in 2025 and is expected to reach USD 19.57 billion by 2032. Across the 7 Major Markets (US, EU4, UK, and Japan), the market reached USD 142.8 million in 2024 and is expected to reach USD 692.7 million by 2035. The US market size for frontotemporal dementia was USD 68 million in 2023 within the 7MM.
AI Analysis | Feedback
Anavex Life Sciences (AVXL) is poised for potential revenue growth over the next 2-3 years, driven primarily by the advancement and prospective commercialization of its lead drug candidates for central nervous system (CNS) diseases. Key drivers include:
- Regulatory Approval and Commercialization of ANAVEX®2-73 (blarcamesine) for Alzheimer's Disease: Anavex is actively engaged in discussions with the U.S. FDA regarding potential pathways to support a New Drug Application (NDA) for blarcamesine as a treatment for Alzheimer's disease. Despite a negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which the company intends to appeal, the ongoing regulatory progress in the U.S. represents a significant opportunity for market entry and revenue generation. Analysts forecast substantial revenue for AVXL in 2027 and 2028, indicating expectations of commercialization for its lead candidate.
- Regulatory Approval and Commercialization of ANAVEX®2-73 (blarcamesine) for Rett Syndrome: ANAVEX®2-73 has successfully completed Phase 2 and Phase 3 studies in adult patients, as well as a Phase 2/3 study in pediatric patients with Rett syndrome. Given its advanced clinical stage and prior Orphan Drug Designation, securing regulatory approval and subsequently launching blarcamesine for Rett syndrome would contribute significantly to future revenue.
- Advancement and Potential Commercialization of ANAVEX®3-71 for Schizophrenia: The company has reported positive topline results from its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia, meeting the primary endpoint of safety and tolerability. Furthermore, the successful development of a once-daily oral tablet formulation with superior pharmacokinetics is expected to facilitate its progression into pivotal clinical studies, moving it closer to potential market entry and revenue generation within the forecast period.
- Progression of ANAVEX®2-73 in Parkinson's Disease: ANAVEX®2-73 has completed a Phase 2 proof-of-concept study for Parkinson's disease dementia. Anavex has listed "Regulatory and clinical trial update for blarcamesine in Parkinson's disease" as an expected development milestone, indicating ongoing efforts to advance this program, which could lead to later-stage trials and eventually revenue within the 2-3 year timeframe.
AI Analysis | Feedback
Share Issuance
- Anavex Life Sciences raised $36.3 million in 2025 by issuing approximately 6.0 million new shares through an at-the-market (ATM) Sales Agreement.
- In mid-2025, the company announced a $150 million at-the-market share sale program.
- Stockholders approved an amendment to the 2022 Omnibus Incentive Plan in June 2025, increasing the number of shares authorized for issuance under the plan by 4 million.
Capital Expenditures
- Anavex Life Sciences has consistently reported $0.0 for Plant, Property, & Equipment (net), indicating minimal to no capital expenditures on physical assets.
- The company's primary investment focus is on research and development (R&D), with R&D expenses for the fourth quarter of fiscal 2025 at $7.3 million.
Latest Trefis Analyses
Trade Ideas
Select ideas related to AVXL.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.68 |
| Mkt Cap | 1.4 |
| Rev LTM | 4 |
| Op Inc LTM | -43 |
| FCF LTM | -30 |
| FCF 3Y Avg | -31 |
| CFO LTM | -30 |
| CFO 3Y Avg | -31 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.3% |
| Rev Chg 3Y Avg | 16.9% |
| Rev Chg Q | 1.9% |
| QoQ Delta Rev Chg LTM | 0.5% |
| Op Inc Chg LTM | -15.9% |
| Op Inc Chg 3Y Avg | -3.4% |
| Op Mgn LTM | 7.4% |
| Op Mgn 3Y Avg | 5.2% |
| QoQ Delta Op Mgn LTM | -2.4% |
| CFO/Rev LTM | 11.3% |
| CFO/Rev 3Y Avg | 11.4% |
| FCF/Rev LTM | 10.7% |
| FCF/Rev 3Y Avg | 7.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.4 |
| P/S | 3.3 |
| P/Op Inc | -3.6 |
| P/EBIT | -3.9 |
| P/E | -3.9 |
| P/CFO | -4.9 |
| Total Yield | -10.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -9.9% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.8% |
| 3M Rtn | -2.3% |
| 6M Rtn | 2.1% |
| 12M Rtn | 34.4% |
| 3Y Rtn | -22.3% |
| 1M Excs Rtn | -0.1% |
| 3M Excs Rtn | -10.7% |
| 6M Excs Rtn | -15.8% |
| 12M Excs Rtn | 16.8% |
| 3Y Excs Rtn | -98.8% |
Price Behavior
| Market Price | $2.91 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -78.3% | |
| 50 Days | 200 Days | |
| DMA Price | $3.53 | $5.87 |
| DMA Trend | down | down |
| Distance from DMA | -17.5% | -50.4% |
| 3M | 1YR | |
| Volatility | 91.7% | 88.1% |
| Downside Capture | 266.22 | 284.85 |
| Upside Capture | 73.28 | 81.15 |
| Correlation (SPY) | 22.1% | 19.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.54 | 1.53 | 1.80 | 1.88 | 1.47 | 1.42 |
| Up Beta | 1.56 | 2.68 | 2.68 | 1.43 | 1.11 | 1.32 |
| Down Beta | 5.28 | -1.24 | -1.00 | 0.66 | 0.88 | 0.60 |
| Up Capture | 251% | 38% | 105% | 123% | 75% | 432% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 14 | 22 | 33 | 62 | 120 | 353 |
| Down Capture | 1130% | 241% | 251% | 241% | 184% | 113% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 18 | 26 | 57 | 124 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVXL | |
|---|---|---|---|---|
| AVXL | -62.5% | 87.6% | -0.69 | - |
| Sector ETF (XLV) | 14.8% | 14.9% | 0.71 | 18.0% |
| Equity (SPY) | 27.4% | 12.1% | 1.71 | 20.2% |
| Gold (GLD) | 42.5% | 26.8% | 1.30 | 4.6% |
| Commodities (DBC) | 45.4% | 18.5% | 1.88 | -3.7% |
| Real Estate (VNQ) | 11.5% | 13.5% | 0.56 | 22.3% |
| Bitcoin (BTCUSD) | -23.7% | 41.8% | -0.54 | 24.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVXL | |
|---|---|---|---|---|
| AVXL | -22.3% | 83.1% | 0.08 | - |
| Sector ETF (XLV) | 4.8% | 14.7% | 0.15 | 28.9% |
| Equity (SPY) | 13.6% | 17.1% | 0.63 | 34.8% |
| Gold (GLD) | 19.4% | 17.9% | 0.88 | 6.5% |
| Commodities (DBC) | 10.9% | 19.4% | 0.45 | 2.1% |
| Real Estate (VNQ) | 2.9% | 18.8% | 0.06 | 32.6% |
| Bitcoin (BTCUSD) | 7.2% | 55.9% | 0.34 | 18.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVXL | |
|---|---|---|---|---|
| AVXL | -4.4% | 85.3% | 0.34 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 23.4% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 29.0% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 5.2% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | 8.2% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.21 | 24.8% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.06 | 11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/9/2026 | 6.1% | -4.1% | 13.2% |
| 11/25/2025 | 12.3% | 48.4% | 18.5% |
| 5/9/2024 | 4.6% | 21.0% | 4.3% |
| 12/28/2020 | -2.0% | -8.1% | 12.7% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 4 |
| # Negative | 1 | 2 | 0 |
| Median Positive | 6.1% | 34.7% | 12.9% |
| Median Negative | -2.0% | -6.1% | |
| Max Positive | 12.3% | 48.4% | 18.5% |
| Max Negative | -2.0% | -8.1% | |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/09/2026 | 10-Q |
| 09/30/2025 | 11/25/2025 | 10-K |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 02/12/2025 | 10-Q |
| 09/30/2024 | 12/23/2024 | 10-K |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/07/2024 | 10-Q |
| 09/30/2023 | 11/27/2023 | 10-K |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/07/2023 | 10-Q |
| 09/30/2022 | 11/28/2022 | 10-K |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 2/9/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | 3 | 0.0% | Affirmed | Guidance: 3 for 2028 | |||
Prior: Q4 2025 Earnings Reported 11/25/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | 3 | -25.0% | Lowered | Guidance: 4 for 2028 | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.